Vernalis PLC: AGM Statement Dec 14, 2017 02:00AM
Vernalis + Daiichi Sankyo Enter Collaboration Dec 13, 2017 02:00AM
Vernalis and Servier Achieve Research Milestone Dec 6, 2017 02:00AM
Vernalis plc: Results Announcement for the year ended 30 June 2017 Sep 12, 2017 02:00AM
Vernalis PLC: FDA Issues Complete Response Letter on CCP-08 NDA Aug 7, 2017 02:08AM


Jul 18, 2017 02:00AM Vernalis PLC: Year-End Trading Update and Notice of Full Year Results
Apr 21, 2017 02:00AM Vernalis PLC: FDA Issues a Complete Response Letter on CCP-07 NDA
Feb 21, 2017 02:00AM Vernalis PLC: Unaudited Interim Results for the six months ended 31 December 2016
Feb 14, 2017 02:00AM Vernalis achieves a $3 million milestone payment from Corvus Pharmaceuticals Inc
Jan 30, 2017 08:14AM Vernalis PLC: Notice of Results for Six Months Ended 31/12/2016
Dec 21, 2016 02:00AM Vernalis PLC: FDA accepts CCP-08 NDA for full review
Dec 1, 2016 02:00AM Vernalis plc: AGM Statement
Sep 29, 2016 02:00AM Vernalis PLC Announces Results Announcement for the 12 Months Ended 30 June 2016
Jul 19, 2016 02:00AM Vernalis Achieves a Milestone in Its Oncology Collaboration With Servier
Jul 15, 2016 02:00AM Vernalis Notes the Acquisition of RedoxTherapies by Juno Therapeutics
Jul 8, 2016 02:00AM Vernalis Announces Successful Completion of CCP-08 Pivotal Multiple-Dose Comparative Bioavailability Study
Jul 7, 2016 09:41AM Year-End Trading Update and Notice of Results
Apr 14, 2016 02:00AM Vernalis Announces Successful Completion of CCP-07 Pivotal Multiple-Dose Comparative Bioavailability Study
Apr 13, 2016 02:00AM Vernalis Announce CCP-08 Single-Dose Study Results
Mar 17, 2016 03:00AM Vernalis plc Announces Unaudited Interim Results Announcement for the Six Months Ended 31 December 2015
Feb 4, 2016 11:19AM Vernalis plc ("Vernalis" or the "Company") Notice of Results for the Six Months Ended 31 December 2015
Jan 6, 2016 02:00AM Vernalis Announces Corvus Pharmaceuticals, Inc. as Its Worldwide Licensee for Their Adenosine Antagonist Program
Dec 21, 2015 02:00AM Vernalis Announces Successful Completion of CCP-07 Pivotal Single-Dose Comparative Bioavailability Study
Dec 2, 2015 02:00AM Vernalis plc ("Vernalis" or the "Company") AGM Statement
Oct 12, 2015 02:00AM Vernalis Announces Start of CCP-08 12 Month Stability Testing
Sep 29, 2015 03:57AM Vernalis PLC: Results announcement for 18 months ended 30/06/15
Sep 8, 2015 02:00AM Vernalis PLC Launches Tuzistra(TM) XR (Codeine Polistirex and Chlorpheniramine Polistirex) for Cough Relief With 12-Hour Dosing
Aug 18, 2015 02:00AM Vernalis plc - Appointment of Non-Executive Director
Jun 30, 2015 09:38AM Vernalis plc - Appointment of Non-Executive Director
Jun 11, 2015 02:00AM Vernalis Announces CCP-07 Starts 12 Month Stability Testing
May 1, 2015 07:00AM Vernalis and Tris Pharma receive FDA approval of NDA for Tuzistra™ XR (codeine polistirex and chlorpheniramine polistirex)
Apr 7, 2015 02:00AM Vernalis plc Enters Into Research Collaboration With Taisho Pharmaceutical Co., Ltd
Mar 6, 2015 02:00AM Vernalis and Asahi Kasei Pharma Achieve Research Milestone